Quarterly report · Q3
3151.TEDINET S100Q4CC
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥443.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥577.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥439.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥1.9bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥4.1bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥336.1bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥346.9bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥233.6bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥213.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥102.4bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥101.3bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥35.2bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥46.59 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.22 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.84 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.25 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | −¥236m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥126m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥426.2bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥418.3bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥77m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥276m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥448.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥440.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥453.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥443.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-12-31 | ¥4.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥2.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-12-31 | −¥119m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥8.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥8.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | ¥36m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥421.5bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥414.9bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6.6bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥1m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥162m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥7.8bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥318m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥443.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥436.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥447.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥439.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 374
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)㈱バイタルケーエスケー・ホールディングス | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都世田谷区弦巻一丁目１番12号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |